Scilex Holding Company is distributing roughly 14 million Semnur Pharmaceuticals shares to eligible stockholders on June 15, 2026 — retaining approximately 172 million of the 186 million Semnur shares it currently holds, a structural detail that tells you everything about the real purpose of this move. This is not a divestiture. It is a loyalty mechanism, designed to align Scilex’s shareholder base with Semnur’s clinical fortunes at a moment when the subsidiary’s lead asset is the most consequential pipeline bet either company has made.
That asset is SP-102 (SEMDEXA), a viscous dexamethasone gel formulated for transforaminal epidural injection in moderate-to-severe sciatica. Its Phase 3 trial, published in PAIN® Journal, hit its primary endpoint — statistically significant pain relief versus placebo at four weeks. The commercial logic behind SP-102 rests on a durable regulatory gap: epidural corticosteroid injections for radicular pain remain off-label, meaning no product in this delivery route carries a sciatica-specific FDA approval. Semnur is chasing that label. Landing it would transform a practice already performed millions of times annually in the U.S. into a market with a named, priced product at its center — a very different commercial situation than the off-label generics currently filling syringes in pain clinics.
The spin-in-miniature structure — one Semnur share per Scilex common share held at the June 1 record date, with the board reserving the right to revoke before payment — mirrors the broader corporate lineage here. Scilex itself was distributed as a taxable dividend from Sorrento Therapeutics in January 2023, so the parent knows how to use a subsidiary stock dividend as both a capital-formation tool and a shareholder retention play. Semnur completed its own SPAC merger with Denali Capital Acquisition Corp. in September 2025 and now trades on OTC Markets under SMNR. Scilex’s overwhelming post-distribution ownership stake means Semnur’s strategic path — including any future financing or partnership — runs entirely through decisions made in Palo Alto.
The single variable worth tracking is whether Semnur files a New Drug Application for SP-102 before Scilex’s commercial revenue base — anchored by ZTlido and ELYXYB — can sustain the subsidiary’s burn independently. An NDA submission date will either validate this entire structural maneuver or expose it as a holding pattern dressed up as a dividend.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
